＊ この共同研究では、分子糊発見を目的としたNeomorphの先進的なディスカバリープラットフォームと、Novo Nordiskが持つカルディオメタボリック疾患および希少疾患に関する広範な専門知識を活用する ＊ マルチターゲットにおける潜在的な取引総額は14億6,000 ...

＊ この共同研究では、分子糊発見を目的としたNeomorphの先進的なディスカバリープラットフォームと、Novo Nordiskが持つカルディオメタボリック疾患および希少疾患に関する広範な専門知識を活用する ＊ マルチターゲットにおける潜在的な取引総額は14億 ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a rapidly growing biotechnology company comprised of industry leading experts in the field of targeted protein degradation (TPD), today announced that it ...

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders for ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to ...

AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of novel molecular glue degraders for multiple targets across oncology and immunology. Under the deal, ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ...